Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

720 ARTÍCULOS , VIENDO DEL 691 AL 705

A review on the new age methodologies for early detection of Alzheimer's and Parkinson's disease

Ghosh N, Sinha K, Sil PC.

Basic Clin Pharmacol Toxicol. 2024 May;134(5):602-613. doi: 10.1111/bcpt.14003. Epub 2024 Mar 14.

[Dementia with Lewy bodies: old and new knowledge-Part 2: treatment]

Dodel R, Berg D, Duning T, Kalbe E, Meyer PT, Ramirez A, Storch A, Aarsland D, Jessen F.

Nervenarzt. 2024 Apr;95(4):362-367. doi: 10.1007/s00115-023-01577-2. Epub 2023 Dec 14.

The Potentiality of Natural Products and Herbal Medicine as Novel Medications for Parkinson's Disease: A Promising Therapeutic Approach

So YJ, Lee JU, Yang GS, Yang G, Kim SW, Lee JH, Kim JU.

Int J Mol Sci. 2024 Jan 15;25(2):1071. doi: 10.3390/ijms25021071.

Molecular insights into the potential effects of selective estrogen receptor β agonists in Alzheimer's and Parkinson's diseases

Rymbai E, Sugumar D, Chakkittukandiyil A, Kothandan R, Selvaraj D.

Cell Biochem Funct. 2024 Apr;42(3):e4014. doi: 10.1002/cbf.4014.

Targeting dysregulated lipid metabolism for the treatment of Alzheimer's disease and Parkinson's disease: Current advancements and future prospects

Tong B, Ba Y, Li Z, Yang C, Su K, Qi H, Zhang D, Liu X, Wu Y, Chen Y, Ling J, Zhang J, Yin X, Yu P.

Neurobiol Dis. 2024 Jun 15;196:106505. doi: 10.1016/j.nbd.2024.106505. Epub 2024 Apr 19.

Silent Information Regulator 1/Peroxisome Proliferator-Activated Receptor-γ Coactivator-1α Axis: A Promising Target for Parkinson's and Alzheimer's Disease Therapies

Goyal A, Kumari A, Verma A, Chaudhary V, Agrawal V, Yadav HN.

J Biochem Mol Toxicol. 2024 Dec;38(12):e70078. doi: 10.1002/jbt.70078.

Luteolin: Nature's promising warrior against Alzheimer's and Parkinson's disease

Goyal A, Solanki K, Verma A.

J Biochem Mol Toxicol. 2024 Jan;38(1):e23619. doi: 10.1002/jbt.23619. Epub 2023 Dec 13.

Nanotechnology-based Drug Delivery for Alzheimer's and Parkinson's Diseases

Nguyen-Thi PT, Ho TT, Nguyen TT, Vo GV.

Curr Drug Deliv. 2024;21(7):917-931. doi: 10.2174/1567201820666230707113405.

Communal interaction of glycation and gut microbes in diabetes mellitus, Alzheimer's disease, and Parkinson's disease pathogenesis

Patil RS, Tupe RS.

Med Res Rev. 2024 Jan;44(1):365-405. doi: 10.1002/med.21987. Epub 2023 Aug 17.

Potential implications of polyphenolic compounds in neurodegenerative diseases

Shi R, Gao D, Stoika R, Liu K, Sik A, Jin M.

Crit Rev Food Sci Nutr. 2024;64(16):5491-5514. doi: 10.1080/10408398.2022.2155106. Epub 2022 Dec 16.

Cholecystokinin (CCK): a neuromodulator with therapeutic potential in Alzheimer's and Parkinson's disease

Reich N, Hölscher C.

Front Neuroendocrinol. 2024 Apr;73:101122. doi: 10.1016/j.yfrne.2024.101122. Epub 2024 Feb 10.

The role of iron transporters and regulators in Alzheimer's disease and Parkinson's disease: Pathophysiological insights and therapeutic prospects

Tian S, Wang B, Ding Y, Zhang Y, Yu P, Chang YZ, Gao G.

Biomed Pharmacother. 2024 Oct;179:117419. doi: 10.1016/j.biopha.2024.117419. Epub 2024 Sep 8.

Selenium-containing compounds: a new hope for innovative treatments in Alzheimer's disease and Parkinson's disease

Pyka P, Garbo S, Fioravanti R, Jacob C, Hittinger M, Handzlik J, Zwergel C, Battistelli C.

Drug Discov Today. 2024 Aug;29(8):104062. doi: 10.1016/j.drudis.2024.104062. Epub 2024 Jun 11.

Tamsulosin use in benign prostatic hyperplasia and risks of Parkinson's disease, Alzheimer's disease and mortality: An observational cohort study of elderly Medicare enrollees

Fung KW, Baye F, Baik SH, McDonald CJ.

PLoS One. 2024 Aug 22;19(8):e0309222. doi: 10.1371/journal.pone.0309222. eCollection 2024.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias